Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression
Brett P. Monia(Ionis Pharmaceuticals (United States)), Sandra Freier(Ionis Pharmaceuticals (United States)), Charles J. Guinosso(Ionis Pharmaceuticals (United States)), Elena A. Lesnik(Ionis Pharmaceuticals (United States)), P. Dan Cook(Ionis Pharmaceuticals (United States)), W.F. Lima(Ionis Pharmaceuticals (United States)), Andrew M. Kawasaki(Ionis Pharmaceuticals (United States)), C. Gonzalez(Ionis Pharmaceuticals (United States)), D. P. C. MCGEE(Ionis Pharmaceuticals (United States))
Cited by 770
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
|Hepatology|2007|1k
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
|New England Journal of Medicine|2014|621